A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

• Status: Completed
• Trial end date: 2008-08-12
• Target enrollment: 0
• Participant gender: All

Summary

A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Valacyclovir

Criteria

Inclusion Criteria:

• Subject has a history of genital HSV documented by laboratory testing at screening

• Subject has experienced 4 or more episodes of genital herpes during the past 12 months

Exclusion Criteria:

• Subject is immunocompromised